Profiling cell signaling pathway activity

Unravelling the molecular phenotype

Want to know more about OncoSignal?

We will get in touch with you as soon as possible.

QIAGEN and Philips collaborate to develop CDX tests based on OncoSignal technology

Watch the Qiagen webinar hosted by FiercePharma (on demand):

Signaling pathway CDx for therapy response prediction

With this webinar, we announce a partnership between QIAGEN and Philips in the development of companion diagnostics based on OncoSignal pathway activity tests for therapy response prediction.

Watch here
View all publications

Recent scientific publication

"Heterogeneity in signaling pathway activity within primary and between primary and metastatic breast cancer", published in Cancers.

In this study, we investigated heterogeneity, using novel assays to measure activity of tumor-driving signal transduction pathways, e.g., estrogen receptor and PI3K pathways, in multiple samples distributed across the tumor and in metastases.

Read our paper
Collaboration with Erasmus MC Cancer Institute to improve the diagnostics of bladder cancer patients

Together with the Erasmus MC Urothelial Cancer Research Group (EUCRG) from the Department of Urology, we have completed a pilot study investigating if OncoSignal is able to predict which high-risk non-muscle-invasive bladder cancer patients treated with BCG have a high risk of developing progressive disease. The promising results have led to a collaboration to perform OncoSignal on a large series of bladder cancer patients.

The aim of this study is to investigate whether OncoSignal could play a supporting role in treatment choice of bladder cancer patients. Since there is currently a global shortage of BCG, alternative treatment strategies for this patient group are essential.

Philips Pathway Activity Profiling OncoSignal

A number of cell signal transduction pathways are known to play a role in the development of cancer. OncoSignal helps to gain insight into the functional activity of these underlying tumor driving signaling pathways. mRNA levels transcribed from direct target genes regulated by the pathway transcription factors are measured and translated into a quantitative pathway activity scores. The activity score of each pathway is reported on a scale from 0 to 100, resulting in a quantitative characterization of the cell molecular phenotype. OncoSignal can support drug development, patient stratification for clinical trials, and cancer research.

For examples on the use of OncoSignal, please request the OncoSignal application note via oncosignal@philips.com.

*For Research Use Only – not for use in diagnostic procedures.

OncoSignal products and services

Test for in-house use

OncoSignal Test

ER, AR, PI3K, MAPK pathways
Compatible with FFPE samples from human origin
RT-qPCR testing plates including quality checks on sample input and correct plate filling

Result overview in dedicated Pathway Activity Profiling Report
Allows for in-house testing using standard laboratory equipment
Developed under ISO13485

Service testing

OncoSignal Service

ER, AR, PI3K, MAPK, Hedgehog, Notch, TGFβ pathways
Compatible with FFPE tissue samples and RNA extracted from cells and tissue of human origin
Extensive quality checks on samples, laboratory process and results
Result overview in dedicated Pathway Activity Profiling Report
ISO13485 certified

Data analysis service

OncoSignal Data Service

ER, AR, PI3K, MAPK, Hedgehog, Notch, TGFβ, Wnt, JAK-STAT1/2*, JAK-STAT3*,

NF-КB* pathways

Compatible with Affymetrix Microarray gene expression data and RNA sequencing data**
Extensive quality checks on samples and results
Result overview in dedicated Pathway Activity Profiling Report

* Under development.
** Please contact us for specific requirements.

OncoSignal is available for Research Use Only – not for use in diagnostic procedures.

Resources

For copies of one of the below mentioned publications and posters, please email us at oncosignal@philips.com.

Scientific publications

• Heterogeneity in signaling pathway activity within primary and between primary and metastatic breast cancer, Cancers 2021

• RNA based approaches to profile oncogenic pathways from low quantity samples to drive precision oncology strategies, Frontiers in Genetics, 2021

• A Molecular Test for Quantifying Functional Notch Signaling Pathway Activity in Human Cancer, Cancers, 2020

• Measurement of Cellular Immune Response to Viral Infection and Vaccination, Frontiers in Immunology, 2020

• Characterization of immunoactive and immunotolerant CD4+ T cells in breast cancer by measuring activity of signaling pathways that determine immune cell function, bioRxiv, 2020

• Signal Transduction Pathway Activity in High-Grade, Serous Ovarian Carcinoma Reveals a More Favorable Prognosis in Tumors with Low PI3K and High NF-КB Pathway Activity: A Novel Approach to a Long-Standing Enigma, Cancers, 2020

• Oestrogen receptor pathway activity is associated with outcome in endometrial cancer, British Journal of Cancer, 2020

ER and PI3K pathway activity in primary ER positive breast cancer is associated with progression-freesurvival of metastatic patients under first-line tamoxifen, Cancers, 2020; Mar 27;12(4):802
Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients, International Journal of Cancer, 2019; Jun 1;146(11):3196-3206. doi: 10.1002/ijc.32795. Epub 2019 Dec 12
Estrogen receptor pathway activity score to predict clinical response or resistance to neo-adjuvant endocrine therapy in primary breast cancer, Molecular Cancer Therapeutics, 2019; Feb;19(2):680-689
Quantitative measurement of functional activity of the PI3K signaling pathway in Cancer; Cancers, 2019; Mar 1;11(3)
Enabling precision medicine by unravelling disease pathophysiology: quantifying signal transduction pathway activity across cell and tissue types; Nature Scientific Reports, 2019; Feb 7;9(1):1603
Assessment of functional phosphatidylinositol 3-kinase pathway activity in cancer tissue using forkhead box-o target gene expression in a knowledge-based computational model; The American Journal of Pathology, 2018; Sep;188(9):1956-1972
Complete sequence-based pathway analysis by differential on-chip DNA and RNA extraction from a single cell, Nature Scientific Reports, 2017; Sep 8;7(1):11030
Knowledge-based computational models, Oncotarget, 2014; Jul 30;5(14):5196-7
Selection of personalized patient therapy through the use of knowledge-based computational models that identify tumor-driving signal transduction pathways, Cancer Research, 2014; Jun 1;74(11):2936-45

Posters

Development of quantitative multi platform tests for easy readout of AR, ER, PI3K and MAPK pathway activity to unravel-pathophysiology across cancer and tissue types (AACR 2020)
First results of the EIT PACMAN Study: OncoSignal pathway analysis to identify clinically actionable signal transduction pathway activity in a variety of cancer types (AACR 2020)
EIT PACMAN Study preliminary results: OncoSignal pathway analysis identifies actionable cancer targets (online abstract, ASCO 2020)
Androgen receptor pathway activity and the ratio between androgen and estrogen receptor pathway activity in breast cancer subtypes (SABCS 2019)
The MAPK pathway is variably active across breast cancer subtypes, and increased activity may be associated with hormonal therapy resistance (SABCS 2019)

A test to quantify notch pathway activity in t cell acute lymphoblastic leukemia patients (ASH 2019)
Fulvestrant resistance in an MCF-7 model for breast cancer is associated with complete loss of ER pathway activity and gain of MAPK-AP1 pathway activity (ANE 2019)
Quantitative measurements of functional activity of the TGFβ and MAPK-AP1 pathways in colon cancer provides information on their role in cancer development and metastasis (ANE 2019)
Changes in ER pathway activity score during neoadjuvant letrozole to assess therapy response and predict disease free survival (DFS) in ER positive breast cancer patients (ESMO 2019)
Exploring candidate signal transduction pathways for targeted therapy in esophageal cancer (ESMO 2019)
Signal transduction pathway activity in normal fallopian tube epithelium and high-grade serous carcinoma (ESGO 2019)
Measuring functional PI3K and NFkB pathway activity to distinguish between short-term and long-term disease-free survivors of high grade serous ovarian cancer (ESGO 2019)
Heterogeneity in signaling pathway activity within primary breast cancer and between primary and metastases (ASCO 2019)
Measuring the activity of multiple signal transduction pathways in cancer using RNA sequencing on cells and FFPE tissue (EACR Cancer Genomics 2019)
ER pathway activity score as a predictive biomarker to improve stratification for neo-adjuvant endocrine therapy (ESMO Breast Congress 2019)
Quantitative measurement of multiple signal transduction pathway activities in cell and tissue culture, including cancer, fibroblasts, and immune cell types: a new way forward to standardization of cell culture experiments (AACR 2019)
Breast cancer induces a tolerogenic state of healthy activated CD4+ T-cells, characterized by reduced PI3K, NFκB, JAK-STAT, Notch, and increased TGFβ pathway activity (AACR 2019)
Elucidating the role of functional signal transduction pathway activity in sensitivity and response of triple negative breast cancer PDxs to PI3K inhibition (SABCS 2018)
Does hormone expression by IHC predict ER pathway activity? An analysis in a metastatic breast cancer patient cohort (SABCS 2018)
Assays for measurement of functional signal transduction pathway activity in any cell or tissue sample (Keystone 2018)
Signal transduction pathway activity before and after neoadjuvant treatment in esophageal cancer (ESMO 2018)
Estrogen receptor pathway activity in endometrial carcinomas and its relation to tumor grade and disease related mortality (ESMO 2018)
Analysis of functional androgen receptor-pathway activity to predict response to androgen deprivation therapy in salivary duct carcinoma (ESMO 2018)
Assessment of functional signal transduction pathway activity in patient-derived tumor xenografts to predict and evaluate therapy response (ENA 2018)
Hedgehog signalling pathway activity in high-grade serous ovarian carcinoma (EACR 2018)
Robust measurement of signal transduction pathway activity in cancer using RNA sequencing on cells and FFPE tissue (AMPEu 2018)
Measuring functional signal transduction pathway activity on breast cancer tissue samples to determine intra-tumor heterogeneity and heterogeneity between primary and metastatic tumors (AACR 2018)
Determination of signal transduction pathway activity in patient-derived xenograft models in comparison with clinical patient tumor samples for a variety of human cancer types, Poster, AACR 2018
Measuring functional PI3K pathway activity in cancer tissue using FOXO target gene expression in a knowledge-based computational model (SABCS 2017)
Assessing functional androgen receptor (AR) pathway activity using a computational model (ESMO 2017)
Oncogenic signal transduction pathway activity in glioblastoma and relation to therapy response (EACR Cancer Genomics 2017)
Analysis of active oncogenic signal transduction pathways in HGS ovarian cancer HH pathway activity associated with platin resistance (AMP 2017)
Elucidating pediatric brain tumor pathophysiology by assessing signal transduction pathway activation (AACR 2017)
Predicting first line tamoxifen response of recurrent ER+ breast cancer patients based on transcriptional activity of signaling pathways (AACR 2016)
Prognosis within different breast cancer subtypes using functional activity of signaling pathways (AACR 2015)
Assessing functional ER pathway activity using a computational pathway model (EACR 2014)
Identifying tumor driving signaling pathways using computational pathway models (AACR 2013)
Personalized cancer treatment selection using computational signaling pathway models (SABCS 2011)

Documentation

General information

OncoSignal Test

Life Sciences brochure download (.pdf) file

Applications in Life Sciences

View the video to learn more about the OncoSignal technology.

View the video to learn more about next generation precision medicine.

Explore OncoSignal Test for in-house use

Measure the activity of the ER, AR, PI3K and MAPK signaling pathway in your molecular biology laboratory.

Discover more

This is what your colleagues say about OncoSignal

“Having information regarding signaling pathways that could underlie critical immunologic populations within the tumor microenvironment may be pivotal in understanding how drugs affect the cancer. I am very interested in new technologies that I can use to investigate signaling pathway activity in cancer cells and immune cells for my research in this area”.

Susan F. Slovin, MD, PhD
Professor of Medicine, Weill-Cornell Medical College
Attending Physician in the Genitourinary Oncology Service,
Sidney Kimmel Center for Prostate and Urologic Cancers,
Memorial Sloan-Kettering Cancer Center, New York, USA
This is what your colleagues say about OncoSignal

“High grade serous ovarian carcinoma is still a hard to treat cancer. During the last 20 years we have hardly seen an improvement of survival rates. Recently, we have demonstrated that OncoSignal helps to understand the molecular mechanisms driving high grade serous ovarian cancer in individual patients helping future selection of more effective personalized therapies with targeted drugs. We aim to start a prospective study to further investigate the potential of OncoSignal in patients with ovarian carcinoma”.

Jurgen M. Piek, MD, PhD

Gynaecological Oncologist, Department of Obstetrics and Gynecology,

Catharina Cancer Institute, Catharina Hospital, Eindhoven, The Netherlands
This is what your colleagues say about OncoSignal

"Nowadays, next-generation sequencing by using large panel is commonly recognized as a useful approach to improve cancer patient care. However, estimating the activity of specific pathways rather than single genes aberration may represent a more relevant approach to propose personalised cancer treatments by identifying the main driving mechanisms in each tumour. In this regard, Oncosignal represents a key innovation that can improve dramatically the capacity of molecular tumor board to recommend the right treatment for the right patient".

Prof. Antoine Italiano, MD, PhD

Head Early Phase Trials and Sarcoma Units, Institut Bergonié, Bordeaux, France

Head Precision Medicine program, Gustave Roussy, Paris, France
This is what your colleagues say about OncoSignal

"OncoSignal Pathway Activity Profiling, a functional assay with a clear read out, has the potential to set a new standard for transforming precision oncology and may provide improved therapy selection options".

Anthony M. Magliocco, MD, PhD

Founder & CEO

Protean BioDiagnostics

Tampa/St. Petersburg, Florida, USA

Clinical Advisory Board

We are pleased to receive guidance and support by international experts:

Carlos L. Arteaga, MD, UT Southwestern Medical Center, Dallas (USA)
Jean-Yves Blay, MD, PhD, Centre Léon Bérard, Lyon (France)
Fabien Calvo, MD, PhD, University of Paris Denis Diderot Medical School, Paris (France)
Carla van Herpen, MD, PhD, Radboud University Medical Center, Nijmegen (NL)
Hatim Husain, MD, University of California, San Diego (USA)
Antoine Italiano, MD, PhD, Gustave Roussy, Villejuif (France)
Cynthia Ma, MD, PhD, Washington University Medical School, St. Louis (USA)
Christophe Massard, MD, PhD, Gustave Roussy, Villejuif (France)
Mika Mustonen, PhD, Adj Prof, Southern Finland Regional Cancer Center, Helsinki University Hospital, Helsinki (Finland)
Patrick Pauwels, MD, PhD, Antwerp University Hospital, Edegem (Belgium)
Mark Pegram, MD, Stanford Cancer Institute, Stanford (USA)
Hans Prenen, MD, PhD, Antwerp University Hospital, Edegem (Belgium)
Dirk de Ruysscher, MD, PhD, Maastro, Maastricht University Medical Center, Maastricht (NL)
Nabil F. Saba, MD, FACP, Emory University School of Medicine, Atlanta (USA)
Cristina Saura, MD, PhD, Vall d'Hebron University Hospital, Barcelona (Spain)
Henk Verheul, MD, PhD, Radboud University Medical Center, Nijmegen (NL)
Susan F. Slovin, MD, PhD, Memorial Sloan Kettering Cancer Center, New York (USA)
Karen Willard-Gallo, PhD, Institut Jules Bordet, Brussels (Belgium)

PACMAN study supported by EIT Health

Functional signaling Pathway ACtivity complementing DNA Mutation ANalysis for precision medicine (PACMAN)

The PACMAN study, in collaboration between Institute Gustave Roussy and Philips, will test how well the OncoSignal solution increases the effectiveness of new, personalized cancer therapy. Significant progress has been made with targeted drugs that block tumor-driving molecular pathways, but it is still difficult to predict how patients will respond. OncoSignal was designed to improve selection of optimal personalized therapy for individual patients and will contribute to disruption of cancer care by moving from treatment based on cancer type to tumor biology. Assessment of the functional molecular phenotype will provide improved therapy response prediction compared to DNA genotyping analysis alone. The project promises to improve clinical outcomes, especially for hard-to-treat cancers, reduce unnecessary side effects from ineffective therapies and save costs due to more effective (personalized) therapies.

First results at ASCO and AACR 2020

• EIT PACMAN Study preliminary results: OncoSignal pathway analysis identifies actionable cancer targets, ASCO 2020

• First results of the EIT PACMAN Study: OncoSignal pathway analysis to identify clinically actionable signal transduction pathway activity in a variety of cancer types, AACR 2020

For more information, please visit www.eithealth.eu/pacman.

Contact us

Philips Molecular Pathway Diagnostics

High Tech Campus 11

5656 AE Eindhoven

The Netherlands

Phone: +31 40 2730155

Email: oncosignal@philips.com

I want to be contacted by a representative

I want to have more information

How can we help you?

Contact information

* This field is mandatory

Country

First name*

First name (phonetic)

Last name*

Last name (phonetic)

Salutation

Academic title

Email address*

Business phone

Company*

Job title

Industry

Function

Specialty

Department

State or Province

City

Address

Zip or Postcode

By specifying your reason for contact we will be able to provide you with a better service.

We work with partners and distributors who may contact you about this Philips product on our behalf.

Follow up information

Preferred method of contact

Best time to call

Estimated time of purchase

Comments

I hereby consent to processing of my personal data and sensitive personal data (if any) and transfer of such data abroad, in accordance with the Privacy Notice that can be found here.

What is cross border data transfer?

I agree on cross-border transfer of personal information.

I hereby agree to receive by email or telephone information about Philips products, services, events and promotions, including information by mail that is appropriate to me, taking into account my activities and preferences, including the Expectations I have indicated / and in this form.

I agree that Philips may share my personal information with authorized resellers of its Philips products and equipment in order to meet my expectations as stated in this form.

I would like to receive marketing related electronic communications about Philips products, services, events, and promotions that may be relevant to me based on my user preferences and behaviour. I can revoke my consent at any time.

Final CEE consent

Profiling cell signaling pathway activity

Unravelling the molecular phenotype

Want to know more about OncoSignal?

QIAGEN and Philips collaborate to develop CDX tests based on OncoSignal technology

Recent scientific publication

"Heterogeneity in signaling pathway activity within primary and between primary and metastatic breast cancer", published in Cancers.

Collaboration with Erasmus MC Cancer Institute to improve the diagnostics of bladder cancer patients

Philips Pathway Activity Profiling OncoSignal

OncoSignal products and services

Test for in-house use

OncoSignal Test

Service testing

OncoSignal Service

Data analysis service

OncoSignal Data Service

Resources

Scientific publications

Posters

Documentation

General information

OncoSignal Test

Applications in Life Sciences

Explore OncoSignal Test for in-house use

Measure the activity of the ER, AR, PI3K and MAPK signaling pathway in your molecular biology laboratory.

This is what your colleagues say about OncoSignal

This is what your colleagues say about OncoSignal

This is what your colleagues say about OncoSignal

This is what your colleagues say about OncoSignal

Clinical Advisory Board

We are pleased to receive guidance and support by international experts:

PACMAN study supported by EIT Health

Functional signaling Pathway ACtivity complementing DNA Mutation ANalysis for precision medicine (PACMAN)

First results at ASCO and AACR 2020

Contact us

Philips Molecular Pathway Diagnostics

Contact information